Claim · 2026-02-26 · snapshot · Stated in source · Supported

Generate Biomedicines' IPO prospectus (26 February 2026) names Michael Nally as its Chief Executive Officer and states that he joined the company in 2021.

One recorded claim. The claim panel gives its qualification, the source passages with their place in each source, and how it was checked.

What it connects

Michael Nally → held role at → Generate Biomedicines

Where it appears

No collection page holds this claim. It is listed with its records in the explorer.

Claim and evidence

Michael Nallyheld role at ↓Generate Biomedicines

Machine-checked, not reviewed by an editorStated in sourceSupported

Supporting evidence: primary · 1 source

Date: 2026-02-26 · snapshot Records dated 2026 →
Role: Chief Executive Officer

Scope and limitsA historical role snapshot; the record does not establish when he became CEO or any later role.

The evidence 01

primary sourceSupports the claim

Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock

Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26

Cite the original source

Cite the original document, not Selekoa. Check these details against it.

Source excerpt

“Our Chief Executive Officer, Michael Nally, M.B.A., joined us in 2021”

Location in source Prospectus summary, leadership

How it was read Retrieved directly from the publisher

Machine-checked · 2026-10-30

Source details and check notes

Authors: Generate Biomedicines, Inc. (filed with the US SEC)
Version: Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30.
Canonical address: Open the canonical source ↗
Accessed: 2026-10-30
Language: English (en)
Attribution: Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26.
Reuse: No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution.
Check notes: Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (11 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review.

Status and meaning

Editorial status. Not reviewed by an editor. An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.

Relation. An institutional role with explicitly scoped time: snapshot, sourced interval, or unknown dates. No continuing appointment is implied.

Date. A role stated in the prospectus of this date; the joining year as stated (2021) is not a tenure start for the CEO title.

Record ID aib-co-nally-generate-ceo-2026